Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal Cancer

NCT04008511 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

54

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Regorafenib
DRUG: Regorafenib
DRUG: Capecitabine
DRUG: Oxaliplatin

Sponsor

China Medical University, China

Collaborators

[object Object]
[object Object]